We have previously shown that nucleoside reverse transcriptase inhibitors (NRTI) reduce NLRP3 assembly in PBMCs of AD patients and enhance amyloid-β autophagy in macrophages, potentially offering therapeutic benefits for Alzheimer’s disease [57]. This evidence concerns the gene NLRP3 and early-onset autosomal dominant Alzheimer disease.